P79.07 Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis

The addition of PD-(L)1 inhibitors to first-line chemotherapy (CT) demonstrated to improve the outcomes of advanced non-small cell lung cancer (NSCLC) patients. Nonetheless, no direct comparison exists between these agents.